RAS inhibitors, beta blockers after discharge improve outcomes in MI with mid range EF
Beta-blocker therapy at discharge in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction (MI) was associated with lower 2-year rates of major adverse cardiac events (MACE). The Renin-angiotensin-system (RAS) inhibitor therapy at discharge after acute MI with heart failure with mildly reduced EF was associated with lower rates of rehospitalization...
Beta-blocker therapy at discharge in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction (MI) was associated with lower 2-year rates of major adverse cardiac events (MACE). The Renin-angiotensin-system (RAS) inhibitor therapy at discharge after acute MI with heart failure with mildly reduced EF was associated with lower rates of rehospitalization due to heart failure. Furthermore, the Patients with mildly reduced LVEF after acute MI had better 2-year clinical outcomes if they were on beta blockers or RAS inhibitors at discharge.The findings suggest that beta blockers and RAS inhibitors can be considered in patients with mildly reduced LVEF after an acute MI in the era of early coronary reperfusion therapy and contemporary optimal medical therapies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd